BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 31613319)

  • 1. Noninvasive Evaluation of GPR119 Agonist Effects on β-Cell Mass in Diabetic Male Mice Using 111In-Exendin-4 SPECT/CT.
    Murakami T; Fujimoto H; Fujita N; Hamamatsu K; Matsumoto K; Inagaki N
    Endocrinology; 2019 Dec; 160(12):2959-2968. PubMed ID: 31613319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive longitudinal quantification of β-cell mass with [
    Fujita N; Fujimoto H; Hamamatsu K; Murakami T; Kimura H; Toyoda K; Saji H; Inagaki N
    FASEB J; 2019 Nov; 33(11):11836-11844. PubMed ID: 31370679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression.
    Kim MK; Cheong YH; Lee SH; Kim TH; Jung IH; Chae Y; Lee JH; Yang EK; Park H; Yang JS; Hong KW
    Biomed Pharmacother; 2021 Dec; 144():112324. PubMed ID: 34678732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G protein-coupled receptor 119 agonist DS-8500a effects on pancreatic β-cells in Japanese type 2 diabetes mellitus patients.
    Watada H; Shiramoto M; Irie S; Terauchi Y; Yamada Y; Shiosakai K; Myobatake Y; Taguchi T
    J Diabetes Investig; 2019 Jan; 10(1):84-93. PubMed ID: 29624887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive in vivo determination of viable islet graft volume by
    Eter WA; Van der Kroon I; Andralojc K; Buitinga M; Willekens SMA; Frielink C; Bos D; Joosten L; Boerman OC; Brom M; Gotthardt M
    Sci Rep; 2017 Aug; 7(1):7232. PubMed ID: 28775287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates.
    Hryciw DH; Patten RK; Rodgers RJ; Proietto J; Hutchinson DS; McAinch AJ
    Expert Opin Investig Drugs; 2024 Mar; 33(3):183-190. PubMed ID: 38372052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and in vivo behaviour of an exendin-4-based MRI probe capable of β-cell-dependent contrast enhancement in the pancreas.
    Clough TJ; Baxan N; Coakley EJ; Rivas C; Zhao L; Leclerc I; Martinez-Sanchez A; Rutter GA; Long NJ
    Dalton Trans; 2020 Apr; 49(15):4732-4740. PubMed ID: 32207493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta Cell Imaging-From Pre-Clinical Validation to First in Man Testing.
    Demine S; Schulte ML; Territo PR; Eizirik DL
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive evaluation of donor and native pancreases following simultaneous pancreas-kidney transplantation using positron emission tomography/computed tomography.
    Murakami T; Nakamura T; Fujimoto H; Fujikura J; Shimizu Y; Miyake KK; Otani D; Sakaki K; Kiyobayashi S; Anazawa T; Nakamoto Y; Inagaki N
    J Diabetes Investig; 2023 Oct; 14(10):1187-1191. PubMed ID: 37377043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic structural analysis-based epitope prediction of Exendin-4 in aqueous solution.
    He J; Li J; Leung K
    Phys Rev E; 2023 Aug; 108(2-1):024403. PubMed ID: 37723773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects.
    Murakami T; Fujimoto H; Fujita N; Hamamatsu K; Yabe D; Inagaki N
    J Diabetes Investig; 2020 Nov; 11(6):1448-1456. PubMed ID: 32323451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acromegaly accompanied by diabetes mellitus and polycystic kidney disease.
    Otani D; Murakami T; Matsubara T; Hojo M; Nakae T; Moriyoshi K; Yasoda A; Usui R; Tatsuoka H; Ogura M; Inagaki N; Yamamoto T
    Endocr J; 2021 Jan; 68(1):103-110. PubMed ID: 32814722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose Selective Arterial Calcium Stimulation Test for Localizing Insulinoma: A Single-center Experience of Five Consecutive Cases.
    Hatoko T; Murakami T; Sone M; Yabe D; Masui T; Nakamoto Y; Furuta A; Uza N; Kodama Y; Harada N; Ogura M; Yasoda A; Inagaki N
    Intern Med; 2020 Oct; 59(19):2397-2403. PubMed ID: 32611954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceritinib-associated hyperglycemia in the Japanese Adverse Drug Event Report Database.
    Fujita H; Murakami T; Tomoike F; Yabe D; Inagaki N
    J Diabetes Investig; 2020 May; 11(3):726-730. PubMed ID: 31663274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Prevascularization on Immunological Environment and Early Engraftment in Subcutaneous Islet Transplantation.
    Inoguchi K; Anazawa T; Fujimoto N; Tada S; Yamane K; Emoto N; Izuwa A; Su H; Fujimoto H; Murakami T; Nagai K; Hatano E
    Transplantation; 2024 May; 108(5):1115-1126. PubMed ID: 38192025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preservation effect of imeglimin on pancreatic β-cell mass: Noninvasive evaluation using
    Fauzi M; Murakami T; Fujimoto H; Botagarova A; Sakaki K; Kiyobayashi S; Ogura M; Inagaki N
    Front Endocrinol (Lausanne); 2022; 13():1010825. PubMed ID: 36246910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive Evaluation of GIP Effects on β-Cell Mass Under High-Fat Diet.
    Kiyobayashi S; Murakami T; Harada N; Fujimoto H; Murata Y; Fujita N; Hamamatsu K; Ikeguchi-Ogura E; Hatoko T; Lu X; Yamane S; Inagaki N
    Front Endocrinol (Lausanne); 2022; 13():921125. PubMed ID: 35909510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular Senescence in Diabetes Mellitus: Distinct Senotherapeutic Strategies for Adipose Tissue and Pancreatic β Cells.
    Murakami T; Inagaki N; Kondoh H
    Front Endocrinol (Lausanne); 2022; 13():869414. PubMed ID: 35432205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging in experimental models of diabetes.
    Coppola A; Zorzetto G; Piacentino F; Bettoni V; Pastore I; Marra P; Perani L; Esposito A; De Cobelli F; Carcano G; Fontana F; Fiorina P; Venturini M
    Acta Diabetol; 2022 Feb; 59(2):147-161. PubMed ID: 34779949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [
    Fujimoto H; Fujita N; Hamamatsu K; Murakami T; Nakamoto Y; Saga T; Ishimori T; Shimizu Y; Watanabe H; Sano K; Harada N; Nakamura H; Toyoda K; Kimura H; Nakagawa S; Hirai M; Murakami A; Ono M; Togashi K; Saji H; Inagaki N
    Front Endocrinol (Lausanne); 2021; 12():717101. PubMed ID: 34489868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.